{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086992","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.092974+00:00","generated_at":"2026-05-31T10:48:30.697002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ironwood Q2 revenue down 12% to $94.4M; cuts FY 2024 guidance on Medicaid pricing","bullets":["Total revenue $94.4M in Q2 2024, down 12% from $107.4M in Q2 2023; FY 2024 guidance revised lower due to pricing pressure.","LINZESS prescription demand up 11% YoY but Medicaid utilization drove pricing headwinds; new-to-brand growth 15%.","GAAP net loss of $0.9M (($0.01)/share) vs $1.06B loss in Q2 2023; adjusted EBITDA of $27.9M vs $(1.03B) last year.","Plans to pursue apraglutide rolling NDA for short bowel syndrome; expects submission in Q1 2025. CNP-104 topline results on track for Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086992","json":"https://secwatch.observer/filing/0001104659-24-086992.json","markdown":"https://secwatch.observer/filing/0001104659-24-086992.md","text":"https://secwatch.observer/filing/0001104659-24-086992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924086992/0001104659-24-086992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924086992/tm2421104d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:48:30.697002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}